Ford guides to low end of 2024 earnings forecast as it slightly tops Wall Street’s third-quarter expectations

Ford guides to low end of 2024 earnings forecast as it slightly tops Wall Street’s third-quarter expectations

Ford and Lincoln vehicles are displayed for sale at a Ford dealership on August 21, 2024 in Glendale, California. Mario Tama | Getty Images DETROIT— Ford Motors guided to the low end of its previously announced 2024 earnings forecast as it slightly topped Wall Street’s third-quarter expectations. The Detroit automaker said Monday it now expects…

Read More
Gap beats earnings and revenue estimates, hikes profit margin outlook as results are posted early

Gap beats earnings and revenue estimates, hikes profit margin outlook as results are posted early

A Gap store in New York, US, on Monday, May 27, 2024. Stephanie Keith | Bloomberg | Getty Images Gap raised its full-year profit outlook on Thursday after seeing better-than-expected results at its largest brand, Old Navy. The apparel company’s fiscal second quarter results were released earlier than planned after the company “inadvertently” posted them…

Read More
Nordstrom shares climb 5% as earnings top estimates, but retailer issues cautious guidance

Nordstrom shares climb 5% as earnings top estimates, but retailer issues cautious guidance

Nordstrom on Tuesday posted earnings that blew past Wall Street’s expectations, indicating the department store is making strides in its efforts to cut costs and boost efficiencies. Although the Seattle-based retailer posted earnings per share that were 25 cents higher than expected, it issued tepid guidance for the full year. Nordstrom now expects adjusted earnings…

Read More
Pfizer beats earnings estimates, hikes full-year outlook as drugmaker cuts costs

Pfizer beats earnings estimates, hikes full-year outlook as drugmaker cuts costs

Kena Betancur | Corbis News | Getty Images Pfizer on Tuesday reported second-quarter revenue and adjusted earnings that blew past expectations and raised its full-year outlook, benefiting from its broad cost-cutting program, better-than-expected sales of its Covid antiviral pill, Paxlovid, and strong non- Covid product sales. The company now expects to book adjusted earnings of…

Read More